Evidently, it is likely that the combinations of selinexor and KRAS G12C inhibitors induce cell-cycle arrest in KRAS G12C–mutant cancer cells by downregulating cyclin B1 and CDK4 expression and upregulating the accumulation of TSP Rb in the nucleus. Here, RB1 is linked to cancer.